# LDL-Cholesterol Lowering Effect of KB2115 as Add on to Ezetimibe

> **NCT00677248** · PHASE2 · COMPLETED · sponsor: **Karo Bio AB** · enrollment: 120 (estimated)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** Ezetimibe and placebo
- **DRUG:** Eprotirome and ezetimibe

## Key facts

- **NCT ID:** NCT00677248
- **Lead sponsor:** Karo Bio AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2008-09
- **Final completion:** 2008-10
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2008-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00677248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00677248, "LDL-Cholesterol Lowering Effect of KB2115 as Add on to Ezetimibe". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00677248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*